Top Tweets for #WeekInOncology
📌 Can tumor DNA predict survival in metastatic prostate cancer? A newly validated genomic classification could transform how clinicians assess prognosis and personalize treatment from the moment metastatic disease is diagnosed.
This is This #WeekinOncology #ProstateCancer and brought to us by @OncoAlert GU Faculty Dr. @nataliagandur 👏🏻
Genomic Classification to Predict Survival in Metastatic Prostate Cancer: Development of Somatic Tumor Risk Assessment for Overall Survival-Prostate
https://t.co/XZVCYQSyoY…
🚨 Can tumor DNA predict survival in metastatic prostate cancer? A newly validated genomic classification could transform how clinicians assess prognosis and personalize treatment from the moment metastatic disease is diagnosed.
This is This #WeekinOncology #ProstateCancer and brought to us by our @OncoAlert GU Faculty Dr. Natalia Gandur
Genomic Classification to Predict Survival in Metastatic Prostate Cancer: Development of Somatic Tumor Risk Assessment for Overall Survival-Prostate
https://t.co/4jsuWG6XXs
Metastatic hormone-sensitive prostate cancer lacks a comprehensive genomic system to predict patient outcomes. Researchers analyzed comprehensive genomic profiling data from 2,484 veterans and identified 16 prognostic genes to create the STRATOS-P classification. The model accurately stratified patients into favorable, intermediate, and unfavorable survival groups, achieving strong validation across independent cohorts.
This 🧬DNA-based tool may improve prognostic precision and support more personalized treatment decisions for patients with metastatic prostate cancer.
@DrChoueiri
@tompowles1
@apolo_andrea
@neerajaiims
@montypal
@Silke_Gillessen
@AOmlin
@brian_rini
@PGrivasMDPhD
@TiansterZhang
@AlbigesL
@cdanicas
@amerseburger
@sonpavde
@DrDanielHeng
@declangmurphy
@seanmmcbride
@HHammersMD
@shilpaonc
@DrRanaMcKay
@scserendipity1
@DrYukselUrun
@scocmem
@ravikanesvaran
@AmandaNizamMD
@drenriquegrande
@BraunMDPhD
@EfstathiouEleni
@nataliagandur
@crisbergerot
@realbowtiedoc
@FernandoOnco
@ElisaAgostinett
@to_be_elizabeth
@MarioBalsaMD
@BRicciutiMD
@HHorinouchi
@UOzkerim
@p_ciracimd
@AmandaNizamMD
@scocmem
@DrMirallas
@mwschoen
@HeenaDesai_
@REtzioni
@TimRebbeck
@KMaxwellLab
Can genomics tell us not only what to treat, but who is most at risk? 🧬
STRATOS-P brings a genomic layer to prognostication in metastatic prostate cancer: from genomic strata to smarter STRATOS-ification 😉
Another great #WeekInOncology by @nataliagandur!!!
Follow @OncoAlert for more!🚨
🚨 Can tumor DNA predict survival in metastatic prostate cancer? A newly validated genomic classification could transform how clinicians assess prognosis and personalize treatment from the moment metastatic disease is diagnosed.
This is This #WeekinOncology #ProstateCancer and brought to us by our @OncoAlert GU Faculty Dr. Natalia Gandur
Genomic Classification to Predict Survival in Metastatic Prostate Cancer: Development of Somatic Tumor Risk Assessment for Overall Survival-Prostate
https://t.co/4jsuWG6XXs
Metastatic hormone-sensitive prostate cancer lacks a comprehensive genomic system to predict patient outcomes. Researchers analyzed comprehensive genomic profiling data from 2,484 veterans and identified 16 prognostic genes to create the STRATOS-P classification. The model accurately stratified patients into favorable, intermediate, and unfavorable survival groups, achieving strong validation across independent cohorts.
This 🧬DNA-based tool may improve prognostic precision and support more personalized treatment decisions for patients with metastatic prostate cancer.
@DrChoueiri
@tompowles1
@apolo_andrea
@neerajaiims
@montypal
@Silke_Gillessen
@AOmlin
@brian_rini
@PGrivasMDPhD
@TiansterZhang
@AlbigesL
@cdanicas
@amerseburger
@sonpavde
@DrDanielHeng
@declangmurphy
@seanmmcbride
@HHammersMD
@shilpaonc
@DrRanaMcKay
@scserendipity1
@DrYukselUrun
@scocmem
@ravikanesvaran
@AmandaNizamMD
@drenriquegrande
@BraunMDPhD
@EfstathiouEleni
@nataliagandur
@crisbergerot
@realbowtiedoc
@FernandoOnco
@ElisaAgostinett
@to_be_elizabeth
@MarioBalsaMD
@BRicciutiMD
@HHorinouchi
@UOzkerim
@p_ciracimd
@AmandaNizamMD
@scocmem
@DrMirallas
@mwschoen
@HeenaDesai_
@REtzioni
@TimRebbeck
@KMaxwellLab
🚨 Can tumor DNA predict survival in metastatic prostate cancer? A newly validated genomic classification could transform how clinicians assess prognosis and personalize treatment from the moment metastatic disease is diagnosed.
This is This #WeekinOncology #ProstateCancer and brought to us by our @OncoAlert GU Faculty Dr. Natalia Gandur
Genomic Classification to Predict Survival in Metastatic Prostate Cancer: Development of Somatic Tumor Risk Assessment for Overall Survival-Prostate
https://t.co/4jsuWG6XXs
Metastatic hormone-sensitive prostate cancer lacks a comprehensive genomic system to predict patient outcomes. Researchers analyzed comprehensive genomic profiling data from 2,484 veterans and identified 16 prognostic genes to create the STRATOS-P classification. The model accurately stratified patients into favorable, intermediate, and unfavorable survival groups, achieving strong validation across independent cohorts.
This 🧬DNA-based tool may improve prognostic precision and support more personalized treatment decisions for patients with metastatic prostate cancer.
@DrChoueiri
@tompowles1
@apolo_andrea
@neerajaiims
@montypal
@Silke_Gillessen
@AOmlin
@brian_rini
@PGrivasMDPhD
@TiansterZhang
@AlbigesL
@cdanicas
@amerseburger
@sonpavde
@DrDanielHeng
@declangmurphy
@seanmmcbride
@HHammersMD
@shilpaonc
@DrRanaMcKay
@scserendipity1
@DrYukselUrun
@scocmem
@ravikanesvaran
@AmandaNizamMD
@drenriquegrande
@BraunMDPhD
@EfstathiouEleni
@nataliagandur
@crisbergerot
@realbowtiedoc
@FernandoOnco
@ElisaAgostinett
@to_be_elizabeth
@MarioBalsaMD
@BRicciutiMD
@HHorinouchi
@UOzkerim
@p_ciracimd
@AmandaNizamMD
@scocmem
@DrMirallas
@mwschoen
@HeenaDesai_
@REtzioni
@TimRebbeck
@KMaxwellLab
📌What if a simple blood test could help us decide when to switch treatments in advanced melanoma? 🧬
Join @OncoAlert & our Faculty Dr. Mario Balsa🇪🇸 for this #WeekinOncology #Melanoma as he discusses how the CAcTUS🌵 trial explores how circulating tumour DNA (ctDNA) could help personalise treatment sequencing for patients with BRAF-mutant melanoma—potentially allowing clinicians to make faster, data-driven decisions.👇🏻
What if a simple blood test could help us decide when to switch treatments in advanced melanoma? 🧬
Join OncoAlert & our Faculty Dr. Mario Balsa🇪🇸 for this #WeekinOncology #Melanoma as he discusses how the CAcTUS🌵 trial explores how circulating tumour DNA (ctDNA) could help personalise treatment sequencing for patients with BRAF-mutant melanoma—potentially allowing clinicians to make faster, data-driven decisions.
Use of circulating tumour DNA to prospectively guide a switch from targeted to immune therapy in BRAF mutant advanced melanoma: the randomised phase II CAcTUS trial
The CAcTUS phase II trial explored whether circulating tumour DNA (ctDNA) could guide treatment sequencing in patients with BRAF-mutant advanced melanoma. Patients received targeted therapy (TT) or checkpoint inhibitor immunotherapy (CPI), with treatment switching based on progression or an 80% reduction in BRAF variant allele frequency. ctDNA results were delivered rapidly, successfully guiding treatment decisions. Findings suggest ctDNA may identify treatment response early and help optimise sequencing, with no new safety concerns observed.
https://t.co/16qHCJKqwz
@BeckiLee
@DrHMShaw
@DamianMullan2
@FlorentMouliere
@hitesh22mistry
@TurajlicLab
📣 Pinging our faculty:
@nataliagandur
@realbowtiedoc
@FernandoOnco
@ElisaAgostinett
@to_be_elizabeth
@MarioBalsaMD
@BRicciutiMD
@HHorinouchi
@UOzkerim
@p_ciracimd
@AmandaNizamMD
@scocmem
@DrVilmaPBarcia
@DraMartinezLago
@DrMirallas
@GIMedOnc
@BettinaRyll
🎗️ Pinging colleagues in melanoma:
@DrBetofMDPhD
@FunchainMD
@CureMelanoma
@Melanoma_doctor
@HTawbi_MDPhD
@Chrystal_Paulos
@JaniceM10
@ProfGLongMIA
@ProfRAScolyer
@JeffGershenwald
@MelanomaAus
@AIMatMelanoma
This week, my turn at #WeekInOncology! 🇪🇸🚨
Can ctDNA tell us when to switch before the scan tells us we have to? 🧬
I break down the CACTUS 🌵 trial, an intriguing attempt to move ctDNA from prognostic biomarker to real-time treatment decision tool in BRAF-mutant melanoma!
@OncoAlert #Melanoma
@_SEOM @myESMO
@hospitalclinic
What if a simple blood test could help us decide when to switch treatments in advanced melanoma? 🧬
Join OncoAlert & our Faculty Dr. Mario Balsa🇪🇸 for this #WeekinOncology #Melanoma as he discusses how the CAcTUS🌵 trial explores how circulating tumour DNA (ctDNA) could help personalise treatment sequencing for patients with BRAF-mutant melanoma—potentially allowing clinicians to make faster, data-driven decisions.
Use of circulating tumour DNA to prospectively guide a switch from targeted to immune therapy in BRAF mutant advanced melanoma: the randomised phase II CAcTUS trial
The CAcTUS phase II trial explored whether circulating tumour DNA (ctDNA) could guide treatment sequencing in patients with BRAF-mutant advanced melanoma. Patients received targeted therapy (TT) or checkpoint inhibitor immunotherapy (CPI), with treatment switching based on progression or an 80% reduction in BRAF variant allele frequency. ctDNA results were delivered rapidly, successfully guiding treatment decisions. Findings suggest ctDNA may identify treatment response early and help optimise sequencing, with no new safety concerns observed.
https://t.co/16qHCJKqwz
@BeckiLee
@DrHMShaw
@DamianMullan2
@FlorentMouliere
@hitesh22mistry
@TurajlicLab
📣 Pinging our faculty:
@nataliagandur
@realbowtiedoc
@FernandoOnco
@ElisaAgostinett
@to_be_elizabeth
@MarioBalsaMD
@BRicciutiMD
@HHorinouchi
@UOzkerim
@p_ciracimd
@AmandaNizamMD
@scocmem
@DrVilmaPBarcia
@DraMartinezLago
@DrMirallas
@GIMedOnc
@BettinaRyll
🎗️ Pinging colleagues in melanoma:
@DrBetofMDPhD
@FunchainMD
@CureMelanoma
@Melanoma_doctor
@HTawbi_MDPhD
@Chrystal_Paulos
@JaniceM10
@ProfGLongMIA
@ProfRAScolyer
@JeffGershenwald
@MelanomaAus
@AIMatMelanoma
Another reminder of the potential of ctDNA to enable adaptive treatment strategies, this time in melanoma 👇🏼
This #WeekInOncology by @MarioBalsaMD @OncoAlert
https://t.co/4WyFP7CwDa
What if a simple blood test could help us decide when to switch treatments in advanced melanoma? 🧬
Join OncoAlert & our Faculty Dr. Mario Balsa🇪🇸 for this #WeekinOncology #Melanoma as he discusses how the CAcTUS🌵 trial explores how circulating tumour DNA (ctDNA) could help personalise treatment sequencing for patients with BRAF-mutant melanoma—potentially allowing clinicians to make faster, data-driven decisions.
Use of circulating tumour DNA to prospectively guide a switch from targeted to immune therapy in BRAF mutant advanced melanoma: the randomised phase II CAcTUS trial
The CAcTUS phase II trial explored whether circulating tumour DNA (ctDNA) could guide treatment sequencing in patients with BRAF-mutant advanced melanoma. Patients received targeted therapy (TT) or checkpoint inhibitor immunotherapy (CPI), with treatment switching based on progression or an 80% reduction in BRAF variant allele frequency. ctDNA results were delivered rapidly, successfully guiding treatment decisions. Findings suggest ctDNA may identify treatment response early and help optimise sequencing, with no new safety concerns observed.
https://t.co/16qHCJKqwz
@BeckiLee
@DrHMShaw
@DamianMullan2
@FlorentMouliere
@hitesh22mistry
@TurajlicLab
📣 Pinging our faculty:
@nataliagandur
@realbowtiedoc
@FernandoOnco
@ElisaAgostinett
@to_be_elizabeth
@MarioBalsaMD
@BRicciutiMD
@HHorinouchi
@UOzkerim
@p_ciracimd
@AmandaNizamMD
@scocmem
@DrVilmaPBarcia
@DraMartinezLago
@DrMirallas
@GIMedOnc
@BettinaRyll
🎗️ Pinging colleagues in melanoma:
@DrBetofMDPhD
@FunchainMD
@CureMelanoma
@Melanoma_doctor
@HTawbi_MDPhD
@Chrystal_Paulos
@JaniceM10
@ProfGLongMIA
@ProfRAScolyer
@JeffGershenwald
@MelanomaAus
@AIMatMelanoma
Another excellent episode of #WeekInOncology. Thanks to @OncoAlert for making it easier to stay up to date, and thanks to @MarioBalsaMD for the clear and insightful discussion
What if a simple blood test could help us decide when to switch treatments in advanced melanoma? 🧬
Join OncoAlert & our Faculty Dr. Mario Balsa🇪🇸 for this #WeekinOncology #Melanoma as he discusses how the CAcTUS🌵 trial explores how circulating tumour DNA (ctDNA) could help personalise treatment sequencing for patients with BRAF-mutant melanoma—potentially allowing clinicians to make faster, data-driven decisions.
Use of circulating tumour DNA to prospectively guide a switch from targeted to immune therapy in BRAF mutant advanced melanoma: the randomised phase II CAcTUS trial
The CAcTUS phase II trial explored whether circulating tumour DNA (ctDNA) could guide treatment sequencing in patients with BRAF-mutant advanced melanoma. Patients received targeted therapy (TT) or checkpoint inhibitor immunotherapy (CPI), with treatment switching based on progression or an 80% reduction in BRAF variant allele frequency. ctDNA results were delivered rapidly, successfully guiding treatment decisions. Findings suggest ctDNA may identify treatment response early and help optimise sequencing, with no new safety concerns observed.
https://t.co/16qHCJKqwz
@BeckiLee
@DrHMShaw
@DamianMullan2
@FlorentMouliere
@hitesh22mistry
@TurajlicLab
📣 Pinging our faculty:
@nataliagandur
@realbowtiedoc
@FernandoOnco
@ElisaAgostinett
@to_be_elizabeth
@MarioBalsaMD
@BRicciutiMD
@HHorinouchi
@UOzkerim
@p_ciracimd
@AmandaNizamMD
@scocmem
@DrVilmaPBarcia
@DraMartinezLago
@DrMirallas
@GIMedOnc
@BettinaRyll
🎗️ Pinging colleagues in melanoma:
@DrBetofMDPhD
@FunchainMD
@CureMelanoma
@Melanoma_doctor
@HTawbi_MDPhD
@Chrystal_Paulos
@JaniceM10
@ProfGLongMIA
@ProfRAScolyer
@JeffGershenwald
@MelanomaAus
@AIMatMelanoma
Can ctDNA tell us when it is time to change course in advanced melanoma?
In this week’s #WeekInOncology by @OncoAlert, our colleague Dr. Mario Balsa 🇪🇸 (@MarioBalsaMD) delivers another excellent, clinically focused review, making a complex sequencing question clear, practical, and highly relevant.
The randomized phase II CAcTUS trial, explored whether rapid changes in circulating tumor DNA could guide switching between targeted therapy and checkpoint immunotherapy in patients with BRAF-mutant advanced #Melanoma.
🧬 ctDNA results were delivered fast enough to guide real-time decisions
📉 An 80% reduction in BRAF variant allele frequency was used as a switching signal
🔄 The strategy may identify response earlier and support more personalized sequencing
✅ No new safety concerns emerged
An innovative trial, and a superb discussion by @MarioBalsaMD on how liquid biopsy could move from monitoring disease to actively guiding treatment.
📖 https://t.co/n6mpFXGsru
@BeckiLee @DrHMShaw @DamianMullan2 @FlorentMouliere @hitesh22mistry @TurajlicLab
📣 Pinging our Faculty
@nataliagandur @realbowtiedoc @FernandoOnco @ElisaAgostinett @to_be_elizabeth @MarioBalsaMD @BRicciutiMD @HHorinouchi @UOzkerim @p_ciracimd @AmandaNizamMD @scocmem @DrVilmaPBarcia @DraMartinezLago @DrMirallas @GIMedOnc @BettinaRyll
🎗️ Pinging colleagues in Melanoma
@DrBetofMDPhD @FunchainMD @CureMelanoma @Melanoma_doctor @HTawbi_MDPhD @Chrystal_Paulos @JaniceM10 @ProfGLongMIA @ProfRAScolyer @JeffGershenwald @MelanomaAus @AIMatMelanoma
#ctDNA #LiquidBiopsy #PrecisionOncology #BRAF #Immunotherapy
What if a simple blood test could help us decide when to switch treatments in advanced melanoma? 🧬
Join OncoAlert & our Faculty Dr. Mario Balsa🇪🇸 for this #WeekinOncology #Melanoma as he discusses how the CAcTUS🌵 trial explores how circulating tumour DNA (ctDNA) could help personalise treatment sequencing for patients with BRAF-mutant melanoma—potentially allowing clinicians to make faster, data-driven decisions.
Use of circulating tumour DNA to prospectively guide a switch from targeted to immune therapy in BRAF mutant advanced melanoma: the randomised phase II CAcTUS trial
The CAcTUS phase II trial explored whether circulating tumour DNA (ctDNA) could guide treatment sequencing in patients with BRAF-mutant advanced melanoma. Patients received targeted therapy (TT) or checkpoint inhibitor immunotherapy (CPI), with treatment switching based on progression or an 80% reduction in BRAF variant allele frequency. ctDNA results were delivered rapidly, successfully guiding treatment decisions. Findings suggest ctDNA may identify treatment response early and help optimise sequencing, with no new safety concerns observed.
https://t.co/16qHCJKqwz
@BeckiLee
@DrHMShaw
@DamianMullan2
@FlorentMouliere
@hitesh22mistry
@TurajlicLab
📣 Pinging our faculty:
@nataliagandur
@realbowtiedoc
@FernandoOnco
@ElisaAgostinett
@to_be_elizabeth
@MarioBalsaMD
@BRicciutiMD
@HHorinouchi
@UOzkerim
@p_ciracimd
@AmandaNizamMD
@scocmem
@DrVilmaPBarcia
@DraMartinezLago
@DrMirallas
@GIMedOnc
@BettinaRyll
🎗️ Pinging colleagues in melanoma:
@DrBetofMDPhD
@FunchainMD
@CureMelanoma
@Melanoma_doctor
@HTawbi_MDPhD
@Chrystal_Paulos
@JaniceM10
@ProfGLongMIA
@ProfRAScolyer
@JeffGershenwald
@MelanomaAus
@AIMatMelanoma
What if a simple blood test could help us decide when to switch treatments in advanced melanoma? 🧬
Join OncoAlert & our Faculty Dr. Mario Balsa🇪🇸 for this #WeekinOncology #Melanoma as he discusses how the CAcTUS🌵 trial explores how circulating tumour DNA (ctDNA) could help personalise treatment sequencing for patients with BRAF-mutant melanoma—potentially allowing clinicians to make faster, data-driven decisions.
Use of circulating tumour DNA to prospectively guide a switch from targeted to immune therapy in BRAF mutant advanced melanoma: the randomised phase II CAcTUS trial
The CAcTUS phase II trial explored whether circulating tumour DNA (ctDNA) could guide treatment sequencing in patients with BRAF-mutant advanced melanoma. Patients received targeted therapy (TT) or checkpoint inhibitor immunotherapy (CPI), with treatment switching based on progression or an 80% reduction in BRAF variant allele frequency. ctDNA results were delivered rapidly, successfully guiding treatment decisions. Findings suggest ctDNA may identify treatment response early and help optimise sequencing, with no new safety concerns observed.
https://t.co/16qHCJKqwz
@BeckiLee
@DrHMShaw
@DamianMullan2
@FlorentMouliere
@hitesh22mistry
@TurajlicLab
📣 Pinging our faculty:
@nataliagandur
@realbowtiedoc
@FernandoOnco
@ElisaAgostinett
@to_be_elizabeth
@MarioBalsaMD
@BRicciutiMD
@HHorinouchi
@UOzkerim
@p_ciracimd
@AmandaNizamMD
@scocmem
@DrVilmaPBarcia
@DraMartinezLago
@DrMirallas
@GIMedOnc
@BettinaRyll
🎗️ Pinging colleagues in melanoma:
@DrBetofMDPhD
@FunchainMD
@CureMelanoma
@Melanoma_doctor
@HTawbi_MDPhD
@Chrystal_Paulos
@JaniceM10
@ProfGLongMIA
@ProfRAScolyer
@JeffGershenwald
@MelanomaAus
@AIMatMelanoma
Mucosal melanoma remains one of the greatest unmet needs in our field! 😡
Perhaps the most important finding wasn’t the clinical outcome, but the biology behind it 🧬
My latest #WeekInOncology for @OncoAlert 👇🏼
This trial didn’t meet its primary endpoint—but it uncovered something potentially more important: the immune signatures that may predict who benefits from peri-operative therapy.
Dear Colleagues, another OncoAlert #Melanoma #WeekinOncology with our Faculty Dr. Mario Balsa from Barcelona, Spain🇪🇸 @hospitalclinic
Dr. Balsa discusses and article out on nature communication: A phase II peri-operative study of pembrolizumab plus lenvatinib for mucosal melanoma
This phase II study evaluated peri-operative pembrolizumab plus lenvatinib in patients with resectable mucosal melanoma. Although the trial did not meet its primary endpoint for pathological complete response, treatment showed clinical activity with manageable safety. Biomarker analyses revealed that activated CD4⁺ and CD8⁺ T cells, persistent T-cell receptor clonotypes, and immune-inflamed tumor environments were associated with better outcomes, offering insights for optimizing personalized peri-operative immunotherapy strategies.
Pinging our faculty
@nataliagandur
@realbowtiedoc
@FernandoOnco
@ElisaAgostinett
@to_be_elizabeth
@MarioBalsaMD
@BRicciutiMD
@HHorinouchi
@UOzkerim
@p_ciracimd
@AmandaNizamMD
@scocmem
@DrVilmaPBarcia
@DraMartinezLago
@DrMirallas
@GIMedOnc
@BettinaRyll
Pinging colleagues In Melanoma
@DrBetofMDPhD
@FunchainMD
@CureMelanoma
@Melanoma_doctor
@HTawbi_MDPhD
@Chrystal_Paulos
@JaniceM10
@ProfGLongMIA
@ProfRAScolyer
@JeffGershenwald
@MelanomaAus
@AIMatMelanoma
🚨 This trial missed its primary endpoint, but may have revealed something even more valuable: the immune signatures of benefit.
Another #Melanoma edition of #WeekInOncology by @OncoAlert, featuring our Faculty colleague Dr. Mario Balsa 🇪🇸 (@MarioBalsaMD) from @hospitalclinic.
Dr. Balsa discusses a new Nature Communications publication:
🧬 A phase II peri-operative study of pembrolizumab + lenvatinib in resectable mucosal melanoma
Key findings:
🔹 The study did not meet its primary endpoint for pathological complete response
🔹 The combination showed clinical activity with manageable safety
🔹 Better outcomes were associated with activated CD4⁺ and CD8⁺ T cells
🔹 Persistent T-cell receptor clonotypes and immune-inflamed tumors emerged as potential predictive features
The key lesson may not be the response rate alone, but the biology identifying who is most likely to benefit from peri-operative immunotherapy.
Excellent clinical and translational perspective from @MarioBalsaMD.
Pinging our Faculty
@nataliagandur @realbowtiedoc @FernandoOnco @ElisaAgostinett @to_be_elizabeth @MarioBalsaMD @BRicciutiMD @HHorinouchi @UOzkerim @p_ciracimd @AmandaNizamMD @scocmem @DrVilmaPBarcia @DraMartinezLago @DrMirallas @GIMedOnc @BettinaRyll
Pinging colleagues in Melanoma
@DrBetofMDPhD @FunchainMD @CureMelanoma @Melanoma_doctor @HTawbi_MDPhD @Chrystal_Paulos @JaniceM10 @ProfGLongMIA @ProfRAScolyer @JeffGershenwald @MelanomaAus @AIMatMelanoma
#MucosalMelanoma #Immunotherapy #Biomarkers #PerioperativeTherapy #OncoAlert
This trial didn’t meet its primary endpoint—but it uncovered something potentially more important: the immune signatures that may predict who benefits from peri-operative therapy.
Dear Colleagues, another OncoAlert #Melanoma #WeekinOncology with our Faculty Dr. Mario Balsa from Barcelona, Spain🇪🇸 @hospitalclinic
Dr. Balsa discusses and article out on nature communication: A phase II peri-operative study of pembrolizumab plus lenvatinib for mucosal melanoma
This phase II study evaluated peri-operative pembrolizumab plus lenvatinib in patients with resectable mucosal melanoma. Although the trial did not meet its primary endpoint for pathological complete response, treatment showed clinical activity with manageable safety. Biomarker analyses revealed that activated CD4⁺ and CD8⁺ T cells, persistent T-cell receptor clonotypes, and immune-inflamed tumor environments were associated with better outcomes, offering insights for optimizing personalized peri-operative immunotherapy strategies.
Pinging our faculty
@nataliagandur
@realbowtiedoc
@FernandoOnco
@ElisaAgostinett
@to_be_elizabeth
@MarioBalsaMD
@BRicciutiMD
@HHorinouchi
@UOzkerim
@p_ciracimd
@AmandaNizamMD
@scocmem
@DrVilmaPBarcia
@DraMartinezLago
@DrMirallas
@GIMedOnc
@BettinaRyll
Pinging colleagues In Melanoma
@DrBetofMDPhD
@FunchainMD
@CureMelanoma
@Melanoma_doctor
@HTawbi_MDPhD
@Chrystal_Paulos
@JaniceM10
@ProfGLongMIA
@ProfRAScolyer
@JeffGershenwald
@MelanomaAus
@AIMatMelanoma
This trial didn’t meet its primary endpoint—but it uncovered something potentially more important: the immune signatures that may predict who benefits from peri-operative therapy.
Dear Colleagues, another OncoAlert #Melanoma #WeekinOncology with our Faculty Dr. Mario Balsa from Barcelona, Spain🇪🇸 @hospitalclinic
Dr. Balsa discusses and article out on nature communication: A phase II peri-operative study of pembrolizumab plus lenvatinib for mucosal melanoma
This phase II study evaluated peri-operative pembrolizumab plus lenvatinib in patients with resectable mucosal melanoma. Although the trial did not meet its primary endpoint for pathological complete response, treatment showed clinical activity with manageable safety. Biomarker analyses revealed that activated CD4⁺ and CD8⁺ T cells, persistent T-cell receptor clonotypes, and immune-inflamed tumor environments were associated with better outcomes, offering insights for optimizing personalized peri-operative immunotherapy strategies.
Pinging our faculty
@nataliagandur
@realbowtiedoc
@FernandoOnco
@ElisaAgostinett
@to_be_elizabeth
@MarioBalsaMD
@BRicciutiMD
@HHorinouchi
@UOzkerim
@p_ciracimd
@AmandaNizamMD
@scocmem
@DrVilmaPBarcia
@DraMartinezLago
@DrMirallas
@GIMedOnc
@BettinaRyll
Pinging colleagues In Melanoma
@DrBetofMDPhD
@FunchainMD
@CureMelanoma
@Melanoma_doctor
@HTawbi_MDPhD
@Chrystal_Paulos
@JaniceM10
@ProfGLongMIA
@ProfRAScolyer
@JeffGershenwald
@MelanomaAus
@AIMatMelanoma
Another excellent #WeekInOncology by @UOzkerim @OncoAlert breaking down the data that could soon shape everyday practice 🫁
With ELEVATE, adjuvant ensartinib takes another major step forward in redefining cure for ALK-positive NSCLC 💥
For patients with ALK-positive lung cancer, surgery may remove the tumor—but it does not eliminate the threat of relapse. The ELEVATE Trial out in NEJM
The #WeekInOncology by @OncoAlert 🚨 Dr. Uğur Özkerim 🇹🇷 breaks down his top #LungCancer 🫁 picks:
@peters_solange
@christine_lovly
@GlopesMd
@DrSanjayPopat
@StephenVLiu
@HenningWillers
@HHorinouchi
@BRicciutiMD
@PercyLeeMD
@jillfeldman4
bensolomon1
@Latinamd
@DrJNaidoo
@barlesi
@UOzkerim
@FernandoOnco
@DrMirallas
@VanitaNoronha
@NarjustFlorezMD
@MartinReck2
@realbowtiedoc
@FernandoOnco
@ElisaAgostinett
@to_be_elizabeth
@MarioBalsaMD
@BRicciutiMD
@HHorinouchi
@UOzkerim
@p_ciracimd
@AmandaNizamMD
@scocmem
@DrVilmaPBarcia
@DraMartinezLago
@DrMirallas
@nataliagandur
@GIMedOnc
@DaisukeKotani
For patients with ALK-positive lung cancer, surgery may remove the tumor—but it does not eliminate the threat of relapse. The ELEVATE Trial out in NEJM
The #WeekInOncology by @OncoAlert 🚨 Dr. Uğur Özkerim 🇹🇷 breaks down his top #LungCancer 🫁 picks:
@peters_solange
@christine_lovly
@GlopesMd
@DrSanjayPopat
@StephenVLiu
@HenningWillers
@HHorinouchi
@BRicciutiMD
@PercyLeeMD
@jillfeldman4
bensolomon1
@Latinamd
@DrJNaidoo
@barlesi
@UOzkerim
@FernandoOnco
@DrMirallas
@VanitaNoronha
@NarjustFlorezMD
@MartinReck2
@realbowtiedoc
@FernandoOnco
@ElisaAgostinett
@to_be_elizabeth
@MarioBalsaMD
@BRicciutiMD
@HHorinouchi
@UOzkerim
@p_ciracimd
@AmandaNizamMD
@scocmem
@DrVilmaPBarcia
@DraMartinezLago
@DrMirallas
@nataliagandur
@GIMedOnc
@DaisukeKotani
HIF-2α inhibition is quickly becoming one of the most fascinating stories in RCC!
A must-read discussion by @nataliagandur on the biology that’s shaping the next generation of kidney cancer therapy 🧬🧡
@OncoAlert #WeekInOncology
Does deeper HIF-2α suppression mean better outcomes in Refractory Clear Cell #KidneyCancer?
We are here with another #WeekInOncology and no other than our faculty Natalia Gandur from Argentina🇦🇷 to guide us through this great publication
Casdatifan shows durable response linked to HIF-2α biology in kidney cancer (ARC-20) out in nature
https://t.co/MBexvfoBeo
Casdatifan, a selective HIF-2α inhibitor, demonstrated meaningful and durable antitumour activity with manageable safety in refractory metastatic clear cell renal cell carcinoma in the 🏹 ARC-20 study. Across 127 patients, confirmed objective response rates were 31–35% and median progression-free survival reached 12.2 months overall. Adverse events were mainly 🩸 anemia and hypoxia, with low discontinuation rates. Biomarker 🧬 analyses showed that greater suppression of erythropoietin and HIF-2α activity correlated with improved clinical outcomes and response.
@DrChoueiri
@tompowles1
@apolo_andrea
@neerajaiims
@montypal
@Silke_Gillessen
@AOmlin
@brian_rini
@PGrivasMDPhD
@TiansterZhang
@AlbigesL
@cdanicas
@amerseburger
@sonpavde
@DrDanielHeng
@declangmurphy
@seanmmcbride
@HHammersMD
@shilpaonc
@DrRanaMcKay
@scserendipity1
@DrYukselUrun
@scocmem
@ravikanesvaran
@AmandaNizamMD
@drenriquegrande
@BraunMDPhD
@EfstathiouEleni
@nataliagandur
@crisbergerot
@PBarataMD
@DrRanaMcKay
@MosheOrnsteinMD
@BradMcG04
Pinging #OncoAlertAF Faculty
@realbowtiedoc
@FernandoOnco
@ElisaAgostinett
@to_be_elizabeth
@MarioBalsaMD
@BRicciutiMD
@HHorinouchi
@UOzkerim
@p_ciracimd
@AmandaNizamMD
@scocmem
@DrVilmaPBarcia
@DraMartinezLago
@DrMirallas
@GIMedOnc
@DaisukeKotani
Does deeper HIF-2α suppression mean better outcomes in Refractory Clear Cell #KidneyCancer?
We are here with another #WeekInOncology and no other than our faculty Natalia Gandur from Argentina🇦🇷 to guide us through this great publication
Casdatifan shows durable response linked to HIF-2α biology in kidney cancer (ARC-20) out in nature
https://t.co/MBexvfoBeo
Casdatifan, a selective HIF-2α inhibitor, demonstrated meaningful and durable antitumour activity with manageable safety in refractory metastatic clear cell renal cell carcinoma in the 🏹 ARC-20 study. Across 127 patients, confirmed objective response rates were 31–35% and median progression-free survival reached 12.2 months overall. Adverse events were mainly 🩸 anemia and hypoxia, with low discontinuation rates. Biomarker 🧬 analyses showed that greater suppression of erythropoietin and HIF-2α activity correlated with improved clinical outcomes and response.
@DrChoueiri
@tompowles1
@apolo_andrea
@neerajaiims
@montypal
@Silke_Gillessen
@AOmlin
@brian_rini
@PGrivasMDPhD
@TiansterZhang
@AlbigesL
@cdanicas
@amerseburger
@sonpavde
@DrDanielHeng
@declangmurphy
@seanmmcbride
@HHammersMD
@shilpaonc
@DrRanaMcKay
@scserendipity1
@DrYukselUrun
@scocmem
@ravikanesvaran
@AmandaNizamMD
@drenriquegrande
@BraunMDPhD
@EfstathiouEleni
@nataliagandur
@crisbergerot
@PBarataMD
@DrRanaMcKay
@MosheOrnsteinMD
@BradMcG04
Pinging #OncoAlertAF Faculty
@realbowtiedoc
@FernandoOnco
@ElisaAgostinett
@to_be_elizabeth
@MarioBalsaMD
@BRicciutiMD
@HHorinouchi
@UOzkerim
@p_ciracimd
@AmandaNizamMD
@scocmem
@DrVilmaPBarcia
@DraMartinezLago
@DrMirallas
@GIMedOnc
@DaisukeKotani
🚨 Could a new era be emerging for metastatic pancreatic cancer?
The #WeekInOncology by @OncoAlert turns the spotlight on GI Oncology, and we're delighted to welcome Dr. Vilma Barcia 🇪🇸 (@DrVilmaPBarcia) as she reviews this week's most relevant advances.
This edition features:
🧬 Two important new publications
🚀 EMA fast-tracks the review of daraxonrasib, a potential breakthrough for metastatic pancreatic cancer.
📄 Paper 1 👉 https://t.co/GU8ogtCka2
📄 Paper 2 👉 https://t.co/rjTri6njYa
📰 EMA Update 👉 https://t.co/3crHH3XWS4
Excellent insights from @DrVilmaPBarcia, bringing the latest evidence into clinical perspective.
@JamesClearyMD @MNagasaka @EelkeGort @AliSchram @MacarullaTeresa @DrAngelaLamarca @ArndtVogel
#GIOncology #PancreaticCancer #WeekInOncology #OncoAlert #PrecisionOncology
Could a New Era Be Emerging for Metastatic Pancreatic Cancer? EMA Fast-Tracks Daraxonrasib Review
The @OncoAlert 🚨 #WeekInOncology in GI Cancer is here and we proudly introduce Dr. Vilma Barcia🇪🇸 who guides us through Two New publications and great news from the EMA (Links to the discussed are ):
Paper 1👉 https://t.co/WzkNnefkHV
Paper 2👉 https://t.co/DN1vPUuZlj
EMA News👉 https://t.co/QzyV4KkH7S
@JamesClearyMD
@MNagasaka
@EelkeGort
@AliSchram
@MacarullaTeresa
@DrAngelaLamarca
@ArndtVogel
Pinging our faculty
@CathyEngMD
@BenWestphalen
@graokane
@NiuSanford
@AndresC27622123
@GillSharlene
@pashtoonkasi
@ARosen380
@KoheiShitara
Pinging #OncoAlertAF Faculty
@nataliagandur
@realbowtiedoc
@FernandoOnco
@ElisaAgostinett
@to_be_elizabeth
@MarioBalsaMD
@BRicciutiMD
@HHorinouchi
@UOzkerim
@p_ciracimd
@AmandaNizamMD
@scocmem
@DrVilmaPBarcia
@DraMartinezLago
@DrMirallas
@GIMedOnc
@DaisukeKotani
Hey hey hey! 🚨
@DrVilmaPBarcia breaks down the science, the clinical data, and what it could mean for practice in this week’s #WeekInOncology by @OncoAlert 🧡
Because in GI cancer, every promising signal deserves a closer (and expert) look 👀
Congrats!! 👏🏼
Could a New Era Be Emerging for Metastatic Pancreatic Cancer? EMA Fast-Tracks Daraxonrasib Review
The @OncoAlert 🚨 #WeekInOncology in GI Cancer is here and we proudly introduce Dr. Vilma Barcia🇪🇸 who guides us through Two New publications and great news from the EMA (Links to the discussed are ):
Paper 1👉 https://t.co/WzkNnefkHV
Paper 2👉 https://t.co/DN1vPUuZlj
EMA News👉 https://t.co/QzyV4KkH7S
@JamesClearyMD
@MNagasaka
@EelkeGort
@AliSchram
@MacarullaTeresa
@DrAngelaLamarca
@ArndtVogel
Pinging our faculty
@CathyEngMD
@BenWestphalen
@graokane
@NiuSanford
@AndresC27622123
@GillSharlene
@pashtoonkasi
@ARosen380
@KoheiShitara
Pinging #OncoAlertAF Faculty
@nataliagandur
@realbowtiedoc
@FernandoOnco
@ElisaAgostinett
@to_be_elizabeth
@MarioBalsaMD
@BRicciutiMD
@HHorinouchi
@UOzkerim
@p_ciracimd
@AmandaNizamMD
@scocmem
@DrVilmaPBarcia
@DraMartinezLago
@DrMirallas
@GIMedOnc
@DaisukeKotani
Another excellent #WeekInOncology update from the @OncoAlert team. Congratulations to @DrVilmaPBarcia for a concise overview of key GI oncology publications and the latest EMA news. Looking forward to the next editions! 👏
Could a New Era Be Emerging for Metastatic Pancreatic Cancer? EMA Fast-Tracks Daraxonrasib Review
The @OncoAlert 🚨 #WeekInOncology in GI Cancer is here and we proudly introduce Dr. Vilma Barcia🇪🇸 who guides us through Two New publications and great news from the EMA (Links to the discussed are ):
Paper 1👉 https://t.co/WzkNnefkHV
Paper 2👉 https://t.co/DN1vPUuZlj
EMA News👉 https://t.co/QzyV4KkH7S
@JamesClearyMD
@MNagasaka
@EelkeGort
@AliSchram
@MacarullaTeresa
@DrAngelaLamarca
@ArndtVogel
Pinging our faculty
@CathyEngMD
@BenWestphalen
@graokane
@NiuSanford
@AndresC27622123
@GillSharlene
@pashtoonkasi
@ARosen380
@KoheiShitara
Pinging #OncoAlertAF Faculty
@nataliagandur
@realbowtiedoc
@FernandoOnco
@ElisaAgostinett
@to_be_elizabeth
@MarioBalsaMD
@BRicciutiMD
@HHorinouchi
@UOzkerim
@p_ciracimd
@AmandaNizamMD
@scocmem
@DrVilmaPBarcia
@DraMartinezLago
@DrMirallas
@GIMedOnc
@DaisukeKotani
Could a New Era Be Emerging for Metastatic Pancreatic Cancer? EMA Fast-Tracks Daraxonrasib Review
The @OncoAlert 🚨 #WeekInOncology in GI Cancer is here and we proudly introduce Dr. Vilma Barcia🇪🇸 who guides us through Two New publications and great news from the EMA (Links to the discussed are ):
Paper 1👉 https://t.co/WzkNnefkHV
Paper 2👉 https://t.co/DN1vPUuZlj
EMA News👉 https://t.co/QzyV4KkH7S
@JamesClearyMD
@MNagasaka
@EelkeGort
@AliSchram
@MacarullaTeresa
@DrAngelaLamarca
@ArndtVogel
Pinging our faculty
@CathyEngMD
@BenWestphalen
@graokane
@NiuSanford
@AndresC27622123
@GillSharlene
@pashtoonkasi
@ARosen380
@KoheiShitara
Pinging #OncoAlertAF Faculty
@nataliagandur
@realbowtiedoc
@FernandoOnco
@ElisaAgostinett
@to_be_elizabeth
@MarioBalsaMD
@BRicciutiMD
@HHorinouchi
@UOzkerim
@p_ciracimd
@AmandaNizamMD
@scocmem
@DrVilmaPBarcia
@DraMartinezLago
@DrMirallas
@GIMedOnc
@DaisukeKotani
Last Seen Hashtags on Sotwe
momsonn
barneytheball
Seen from United States
นัดเย็ดเมืองเลย
Seen from Thailand
cleanmyass
Seen from Pakistan
losaga
Seen from United States
omegle
Seen from United States
sister blowjob
Seen from Netherlands
omegle (((**********)))*********** filter:videos
Seen from Jordan
gaziantepeskort
Seen from Turkey
nolimits nolimits
Seen from United States
Most Popular Users
Elon Musk 
@elonmusk
241.5M followers
Barack Obama
@barackobama
119.1M followers
Cristiano Ronaldo
@cristiano
113.8M followers
Donald J. Trump
@realdonaldtrump
111.8M followers
Narendra Modi
@narendramodi
107.2M followers
Rihanna
@rihanna
98.6M followers
NASA
@nasa
92.4M followers
Justin Bieber
@justinbieber
91.7M followers
KATY PERRY
@katyperry
89.6M followers
Taylor Swift
@taylorswift13
83.5M followers
Lady Gaga
@ladygaga
75M followers
Virat Kohli
@imvkohli
72.8M followers
Kim Kardashian
@kimkardashian
70.7M followers
YouTube
@youtube
68.8M followers
Neymar Jr
@neymarjr
65.7M followers
Bill Gates
@billgates
64.9M followers
Selena Gomez
@selenagomez
62.7M followers
The Ellen Show
@theellenshow
62.3M followers
CNN
@cnn
61.8M followers
X
@x
60.8M followers